Market Research Report Viral Conjunctivitis Pipeline Review | Page 2

the therapeutics under development for Viral Conjunctivitis (Ophthalmology),
complete with analysis by stage of development, drug target, mechanism of action
(MoA), route of administration (RoA) and molecule type. The guide covers the
descriptive pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases.
The Viral Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players
involved in therapeutic development for Viral Conjunctivitis and features dormant
and discontinued projects. The guide covers therapeutics under Development by
Companies /Universities /Institutes, the molecules developed by Companies in
Phase II, Phase I and Preclinical stages are 2, 1 and 5 respectively.
Viral Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and
tracking emerging players in the market and their portfolios, enhances decision
making capabilities and helps to create effective counter strategies to gain
competitive advantage. The guide is built using data and information sourced from
Global Markets Directs proprietary databases, company/university websites, clinical
trial registries, conferences, SEC filings, investor presentations and featured press
releases from company/university sites and industry-specific third party sources.
Additionally, various dynamic tracking processes ensure that the most recent
developments are captured on a real time basis.
Scope:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Viral
Conjunctivitis (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Viral Conjunctivitis
(Ophthalmology) by companies and universities/research institutes based on
information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development
ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products
which comprise, product description, descriptive licensing and collaboration details,
R&D brief, MoA & other developmental activities.